AI Article Synopsis

  • Autoimmune lymphoproliferative syndrome (ALPS) is a rare immune disorder marked by issues with cell death regulation, leading to symptoms like lymph node enlargement, autoimmune issues, and higher lymphoma risk, along with a specific cell type (DNTs) accumulating in the body.
  • Genetic mutations are a primary cause, often identified through a complex and expensive method called Sanger sequencing, which can be unreliable for some patients.
  • This study introduced a newer method using deep amplicon sequencing to track a specific mutation (c.718_719insGTCG) over five years, successfully detecting it in various sample times and showing a strong link between DNT counts and the mutation’s presence.

Article Abstract

Autoimmune lymphoproliferative syndrome (ALPS) is a rare primary immune disorder characterized by impaired apoptotic homeostasis. The clinical characteristics include lymphoproliferation, autoimmunity (mainly cytopenia), and an increased risk of lymphoma. A distinctive biological feature is accumulation (>2.5%) of an abnormal cell subset composed of TCRαβ CD4CD8 T cells (DNTs). The most common genetic causes of ALPS are monoallelic pathogenic variants in the gene followed by somatic variants, mainly restricted to DNTs. Identification of somatic variants has been typically addressed by Sanger sequencing in isolated DNTs. However, this approach can be costly and technically challenging, and may not be successful in patients with normal DNT counts receiving immunosuppressive treatment. In this study, we identified a novel somatic mutation in (c.718_719insGTCG) by Sanger sequencing on purified CD3 cells. We then followed the evolutionary dynamics of the variant along time with an NGS-based approach involving deep amplicon sequencing (DAS) at high coverage (20,000-30,000x). Over five years of clinical follow-up, we obtained six blood samples for molecular study from the pre-treatment (DNTs>7%) and treatment (DNTs<2%) periods. DAS enabled detection of the somatic variant in all samples, even the one obtained after five years of immunosuppressive treatment (DNTs: 0.89%). The variant allele frequency (VAF) range was 4%-5% in pre-treatment samples and <1.5% in treatment samples, and there was a strong positive correlation between DNT counts and VAF (Pearson's R: 0.98, p=0.0003). We then explored whether the same approach could be used in a discovery setting. In the last follow-up sample (DNT: 0.89%) we performed somatic variant calling on the exon 9 DAS data from whole blood and purified CD3 cells using VarScan 2. The c.718_719insGTCG variant was identified in both samples and showed the highest VAF (0.67% blood, 1.58% CD3 cells) among >400 variants called. In summary, our study illustrates the evolutionary dynamics of a somatic mutation before and during immunosuppressive treatment. The results show that pathogenic somatic variants can be identified with the use of DAS in whole blood of ALPS patients regardless of their DNT counts.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716137PMC
http://dx.doi.org/10.3389/fimmu.2022.1014984DOI Listing

Publication Analysis

Top Keywords

evolutionary dynamics
8
autoimmune lymphoproliferative
8
lymphoproliferative syndrome
8
somatic variants
8
sanger sequencing
8
detection evolutionary
4
somatic
4
dynamics somatic
4
somatic fas
4
variants
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!